EN | RU
EN | RU

Help Support

Back

Tegoprazan: An effective and safe therapeutic agent to treat NERD

Tegoprazan: An effective and safe therapeutic agent to treat NERD Tegoprazan: An effective and safe therapeutic agent to treat NERD
Tegoprazan: An effective and safe therapeutic agent to treat NERD Tegoprazan: An effective and safe therapeutic agent to treat NERD

What's new?

Tegoprazan was found to offer effective and sustained symptom relief to NERD patients.

In non-erosive reflux disease (NERD) people, oral administration of 50 and 100 mg of tegoprazan demonstrated a favorable safety profile and superior efficacy than placebo in a phase 3 randomized clinical trial. This multicentre, double-blind, placebo-controlled study was carried to investigate the safety and efficacy profiles of tegoprazan (a novel, fast- and long-acting potassium-competitive acid blocker) in comparison with placebo in 324 Korean people suffering from NERD.

Participants were randomly allocated into three therapy groups: 50 mg tegoprazan (n=108), 100 mg tegoprazan (n=108) and placebo (n=108) given once daily for four weeks. The percentage of people with complete resolution of major symptoms (both regurgitation and heartburn) for the last seven days of the four-week therapy period was the major outcome parameter. In addition, other outcomes associated with tolerability, efficacy, and safety were also assessed.

The proportion of people demonstrating complete resolution of major symptoms at week four after receiving placebo and tegoprazan is shown in Table 1:


Both the doses of tegoprazan depicted superior efficacy compared to placebo. Compared to placebo-recipients, both the tegoprazan arms displayed a substantially greater percentage of heartburn-free days and complete resolution rates of heartburn. No profound differences were witnessed in the occurrence of treatment-emergent side effects. Thus, tegoprazan is an effective therapeutic agent for the management of NERD.

Source:

Alimentary Pharmacology & Therapeutics

Article:

Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease

Authors:

Seung Han Kim et al.

Comments (0)

Recommendations

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: